NAFLD in children

new genes, new diagnostic modalities and new drugs

Valerio Nobili, Anna Alisi, Luca Valenti, Luca Miele, Ariel E. Feldstein, Naim Alkhouri

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Nonalcoholic fatty liver disease (NAFLD) has rapidly become the most common form of chronic liver disease in children and adolescents. Over the past 5 years, developments have revolutionized our understanding of the genetic factors, natural history, diagnostic modalities and therapeutic targets for this disease. New polymorphisms, such as those in PNPLA3, TM6SF2, MBOAT7 and GCKR, have been identified and used to predict the development and severity of NAFLD in both adults and children, and their interaction with environmental factors has been elucidated. Studies have demonstrated the true burden of paediatric NAFLD and its progression to end-stage liver disease in adulthood. In particular, nonalcoholic steatohepatitis can progress to advanced fibrosis and cirrhosis, emphasizing the importance of early diagnosis. Non-invasive imaging tests, such as transient elastography, will probably replace liver biopsy for the diagnosis of nonalcoholic steatohepatitis and the assessment of fibrosis severity in the near future. The therapeutic landscape is also expanding rapidly with the development of drugs that can modify liver steatosis, inflammation and fibrosis, indicating that pharmacotherapy for NAFLD will become available in the future. In this Review, we summarize current knowledge and new advances related to the pathogenesis and management of paediatric NAFLD.

Original languageEnglish
Pages (from-to)517-530
JournalNature Reviews Gastroenterology and Hepatology
Volume16
Issue number9
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Pharmaceutical Preparations
Genes
Fibrosis
Pediatrics
Elasticity Imaging Techniques
End Stage Liver Disease
Fatty Liver
Non-alcoholic Fatty Liver Disease
Natural History
Liver Cirrhosis
Disease Progression
Liver Diseases
Early Diagnosis
Chronic Disease
Inflammation
Biopsy
Drug Therapy
Liver
Therapeutics

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

NAFLD in children : new genes, new diagnostic modalities and new drugs. / Nobili, Valerio; Alisi, Anna; Valenti, Luca; Miele, Luca; Feldstein, Ariel E.; Alkhouri, Naim.

In: Nature Reviews Gastroenterology and Hepatology, Vol. 16, No. 9, 01.01.2019, p. 517-530.

Research output: Contribution to journalReview article

@article{ca7caba07e634d1d830855a0ce9a53fd,
title = "NAFLD in children: new genes, new diagnostic modalities and new drugs",
abstract = "Nonalcoholic fatty liver disease (NAFLD) has rapidly become the most common form of chronic liver disease in children and adolescents. Over the past 5 years, developments have revolutionized our understanding of the genetic factors, natural history, diagnostic modalities and therapeutic targets for this disease. New polymorphisms, such as those in PNPLA3, TM6SF2, MBOAT7 and GCKR, have been identified and used to predict the development and severity of NAFLD in both adults and children, and their interaction with environmental factors has been elucidated. Studies have demonstrated the true burden of paediatric NAFLD and its progression to end-stage liver disease in adulthood. In particular, nonalcoholic steatohepatitis can progress to advanced fibrosis and cirrhosis, emphasizing the importance of early diagnosis. Non-invasive imaging tests, such as transient elastography, will probably replace liver biopsy for the diagnosis of nonalcoholic steatohepatitis and the assessment of fibrosis severity in the near future. The therapeutic landscape is also expanding rapidly with the development of drugs that can modify liver steatosis, inflammation and fibrosis, indicating that pharmacotherapy for NAFLD will become available in the future. In this Review, we summarize current knowledge and new advances related to the pathogenesis and management of paediatric NAFLD.",
author = "Valerio Nobili and Anna Alisi and Luca Valenti and Luca Miele and Feldstein, {Ariel E.} and Naim Alkhouri",
year = "2019",
month = "1",
day = "1",
doi = "10.1038/s41575-019-0169-z",
language = "English",
volume = "16",
pages = "517--530",
journal = "Nature Reviews Gastroenterology and Hepatology",
issn = "1759-5045",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - NAFLD in children

T2 - new genes, new diagnostic modalities and new drugs

AU - Nobili, Valerio

AU - Alisi, Anna

AU - Valenti, Luca

AU - Miele, Luca

AU - Feldstein, Ariel E.

AU - Alkhouri, Naim

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Nonalcoholic fatty liver disease (NAFLD) has rapidly become the most common form of chronic liver disease in children and adolescents. Over the past 5 years, developments have revolutionized our understanding of the genetic factors, natural history, diagnostic modalities and therapeutic targets for this disease. New polymorphisms, such as those in PNPLA3, TM6SF2, MBOAT7 and GCKR, have been identified and used to predict the development and severity of NAFLD in both adults and children, and their interaction with environmental factors has been elucidated. Studies have demonstrated the true burden of paediatric NAFLD and its progression to end-stage liver disease in adulthood. In particular, nonalcoholic steatohepatitis can progress to advanced fibrosis and cirrhosis, emphasizing the importance of early diagnosis. Non-invasive imaging tests, such as transient elastography, will probably replace liver biopsy for the diagnosis of nonalcoholic steatohepatitis and the assessment of fibrosis severity in the near future. The therapeutic landscape is also expanding rapidly with the development of drugs that can modify liver steatosis, inflammation and fibrosis, indicating that pharmacotherapy for NAFLD will become available in the future. In this Review, we summarize current knowledge and new advances related to the pathogenesis and management of paediatric NAFLD.

AB - Nonalcoholic fatty liver disease (NAFLD) has rapidly become the most common form of chronic liver disease in children and adolescents. Over the past 5 years, developments have revolutionized our understanding of the genetic factors, natural history, diagnostic modalities and therapeutic targets for this disease. New polymorphisms, such as those in PNPLA3, TM6SF2, MBOAT7 and GCKR, have been identified and used to predict the development and severity of NAFLD in both adults and children, and their interaction with environmental factors has been elucidated. Studies have demonstrated the true burden of paediatric NAFLD and its progression to end-stage liver disease in adulthood. In particular, nonalcoholic steatohepatitis can progress to advanced fibrosis and cirrhosis, emphasizing the importance of early diagnosis. Non-invasive imaging tests, such as transient elastography, will probably replace liver biopsy for the diagnosis of nonalcoholic steatohepatitis and the assessment of fibrosis severity in the near future. The therapeutic landscape is also expanding rapidly with the development of drugs that can modify liver steatosis, inflammation and fibrosis, indicating that pharmacotherapy for NAFLD will become available in the future. In this Review, we summarize current knowledge and new advances related to the pathogenesis and management of paediatric NAFLD.

UR - http://www.scopus.com/inward/record.url?scp=85068860804&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068860804&partnerID=8YFLogxK

U2 - 10.1038/s41575-019-0169-z

DO - 10.1038/s41575-019-0169-z

M3 - Review article

VL - 16

SP - 517

EP - 530

JO - Nature Reviews Gastroenterology and Hepatology

JF - Nature Reviews Gastroenterology and Hepatology

SN - 1759-5045

IS - 9

ER -